[Role of ceftaroline in skin and soft tissue infections].
Skin and soft tissue infections (SSTI) are relatively common. Although most of these infections are mild, a few are severe, requiring hospital admission for intravenous antimicrobial therapy and, fairly frequently, surgery. These infections can be produced by any microorganism, but the most frequent is Staphylococcus aureus. Traditionally, the bacteria causing community-acquired SSTI have been sensitive to antimicrobial agents but this situation has changed with the dissemination of community-acquired microbial resistance, as has occurred in many countries with the increase in methicillin-resistant S. aureus (MRSA). These changes complicate empirical therapy and increase the risk of monotherapy being insufficient to cover all the diagnostic possibilities of SSTI. Within this epidemiological framework, ceftaroline, because of its activity against MRSA, can be used as empirical monotherapy for SSTI.
Unidad de Gestión Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, España. Electronic address: jmcisnerosh@gmail.com.
José Miguel
JM
Cisneros
Servicio de Enfermedades Infecciosas, Hospital Universitario Montepríncipe, Universidad CEU-San Pablo, Madrid, España.
José
J
Barberán
D002511:Cephalosporins / Q000627:therapeutic use*; D006801:Humans; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D018461:Soft Tissue Infections / Q000188:drug therapy*; D000097583:Ceftaroline
D002511:Cephalosporins; D000097583:Ceftaroline
Ceftarolina; Ceftaroline; Infecciones de piel y partes blandas; Methicillin-resistant Staphylococcus; Skin and soft tissue infections; Staphylococcus aureus; Staphylococcus resistente a la meticilina